Trial Profile
The safety and efficacy of recombinant neuregulin-1 (rhNRG-1) in patients with stable chronic heart failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2019 Status changed from recruiting to completed.
- 30 Jun 2016 New trial record